Department of Gastroenterology and Hepatology, Flinders Medical Centre, Southern Adelaide Local Health Network, Flinders Drive, Bedford Park, Adelaide, South Australia, 5042, Australia.
Cancer Research, Flinders Health and Medical Research, Flinders University, Bedford Park, South Australia, Australia.
Dig Dis Sci. 2022 May;67(5):1843-1849. doi: 10.1007/s10620-021-06986-4. Epub 2021 May 3.
Many colonoscopies following a positive fecal immunochemical test (FIT) will not identify a probable cause for fecal blood, and missed neoplasia is a concern. The study determined whether the absence of neoplasia at a FIT positive diagnostic colonoscopy was due to a missed lesion and whether the initial FIT hemoglobin (f-Hb) concentration could predict missed lesions.
This was a retrospective audit of patients who had undergone diagnostic colonoscopy after FIT screening (2 sample ≥ 20 µg Hb/g feces). Probable bleeding lesions including cancer, advanced adenoma, colitis, and angiodysplasia were considered a "positive colonoscopy outcome." For those with a negative outcome, findings at the subsequent colonoscopy were assessed.
There were 1087 good quality colonoscopies within 12 months of a positive FIT. In total, 171 (15.7%) patients had a positive outcome at the diagnostic colonoscopy. Subsequent colonoscopies of negative outcome cases (n = 418, median of 3.1y later) were reviewed; of these, there were 57 (13.6%) cases with a positive outcome. This included CRC in 0.5% (n = 2) and advanced adenoma in 11.7% (n = 49). High f-Hb and having both FIT samples ≥ 20 µg/g feces were associated with a positive outcome at the original diagnostic colonoscopy (p < 0.05). However, f-Hb was not predictive for a positive outcome at the subsequent colonoscopy by either maximum f-Hb (p = 0.768), total f-Hb (p = 0.459), or both FIT samples ≥ 20 µg/g (p = 0.091).
A small proportion of "false" positive FIT results had cancer or advanced adenoma found at the subsequent colonoscopy. A missed lesion could not be predicted by the initial FIT f-Hb.
许多阳性粪便免疫化学检测(FIT)后的结肠镜检查未能确定粪便潜血的可能原因,并且存在漏诊肿瘤是一个关注点。本研究旨在确定 FIT 阳性诊断性结肠镜检查中无肿瘤是否归因于漏诊病变,以及初始 FIT 血红蛋白(f-Hb)浓度是否可预测漏诊病变。
这是一项回顾性审计研究,对象为 FIT 筛查后行诊断性结肠镜检查的患者(2 份样本 ≥ 20 µg Hb/g 粪便)。包括癌症、高级腺瘤、结肠炎和血管发育不良在内的可能出血病变被认为是“阳性结肠镜检查结果”。对于结果为阴性的患者,评估其随后结肠镜检查的结果。
在 FIT 阳性后 12 个月内,共有 1087 例高质量结肠镜检查。在总共 171 例(15.7%)诊断性结肠镜检查阳性的患者中。随后对阴性结果病例(n = 418,中位时间为 3.1 年)的结肠镜检查结果进行了复查;其中,有 57 例(13.6%)结果为阳性。这包括 CRC 病例 0.5%(n = 2)和高级腺瘤病例 11.7%(n = 49)。高 f-Hb 和 2 份 FIT 样本均 ≥ 20 µg/g 粪便与初始诊断性结肠镜检查的阳性结果相关(p < 0.05)。然而,无论是最大 f-Hb(p = 0.768)、总 f-Hb(p = 0.459)还是 2 份 FIT 样本均 ≥ 20 µg/g(p = 0.091),f-Hb 均不能预测后续结肠镜检查的阳性结果。
一小部分“假”阳性 FIT 结果在随后的结肠镜检查中发现了癌症或高级腺瘤。初始 FIT f-Hb 不能预测漏诊病变。